The Vivity Extended Range of Vision IOL vs the PanOptix Trifocal, ReStor 2.5 Active Focus and ReStor 3.0 Multifocal Lenses: A Comparison of Patient Satisfaction, Visual Disturbances, and Spectacle Independence

John A Hovanesian1
Michael Jones2
Quentin Allen3

1Harvard Eye Associates, Laguna Hills, CA, USA; 2Quantum Vision Centers, Swansea, IL, USA; 3Florida Vision Institute, Stuart, FL, USA

Purpose: To compare patient-reported outcomes (PROs) after intraocular lens (IOL) implantation with the AcrySof IQ Vivity IOL or Vivity Toric IOL to those achieved with other multifocal IOLs.

Patients and Methods: Prospective, open-label, multicenter analysis of PROs, including spectacle independence, dysphotopsia, and overall satisfaction among patients who underwent cataract surgery at least 1 month previously with bilateral Vivity or Vivity Toric lenses (n=60). Results were compared to outcomes from two similar prospective studies of bilateral AcrySof IQ PanOptix or PanOptix Toric trifocal IOLs (n = 59), blended AcrySof ReSTOR 2.5/3.0 IOLs (n=72) or bilateral ReSTOR ActiveFocus 2.5 D IOLs with a mini-monovision target [n = 95].

Results: Patients in the Vivity cohort were significantly less likely to notice glare and halo in dim light (85% “none” or “just a little”) compared to PanOptix (69%, p<0.03), 2.5 mini-monovision (75%, p< 0.05) or 2.5/3.0 (71%, p< 0.05) patients. Complete spectacle independence for all visual activities combined (never need glasses) with Vivity was comparable to the mini-monovision and 2.5/3.0 groups (33%, 36%, and 31%, respectively) but significantly lower than in the PanOptix cohort (83%, p < 0.0001). Satisfaction was high across all groups. There were no statistically significant differences in best-corrected visual acuity, and no new safety concerns were reported.

Conclusion: The AcrySof IQ Vivity extended depth of focus IOL offers an expanded range of vision and better spectacle independence than has typically been achieved with traditional monofocal IOLs, with high rates of satisfaction and a favorable dysphotopsia profile compared to diffractive multifocal IOLs.

Keywords: cataract surgery, spectacle independence, glare, multifocal intraocular lens

Plain-Language Summary

In this prospective, open-label, multicenter analysis evaluating patient-reported outcomes 1 month after scheduled cataract surgery, patients reported lower rates of dysphotopsia with the AcrySof IQ Vivity IOL compared to other multifocal IOLs tested, but were more likely to need spectacles for reading than patients with PanOptix IOLs.

Introduction

Older Americans more likely than in previous generations to be working and active, leading to increased visual demands and expectations of cataract surgery.1 Internet
and smartphone usage by Americans over age 65 has risen significantly in the past decade, increasing the need for functional vision and spectacle independence at near, intermediate, and distance post-cataract surgery.

Historically, diffractive multifocal IOLs have provided improved visual acuity at near and intermediate distances and a greater likelihood of spectacle independence than monofocal IOLs. However, patients implanted with these IOLs have noted more frequent dysphotopsia (unwanted visual phenomena) and worse contrast sensitivity, especially in low-light or glare conditions, than do patients implanted with monofocal lenses. In guiding patients who are considering cataract surgery with advanced technology IOLs, it is important for surgeons to understand not only the objective visual acuity outcomes achieved in clinical trials, but also patients’ subjective experience with the IOLs.

The AcrySof IQ ReSTOR +3.0 D multifocal IOL (Alcon, Ft. Worth, Texas), along with its toric counterpart, has been widely perceived by surgeons as providing distance and near vision with some sacrifice in intermediate, while the subsequent ReSTOR +2.5 D helped patients achieve distance and intermediate with some limitations at near. The Panoptix trifocal IOL addressed all three ranges of vision.

Our previous work compared patient-reported outcomes (PROs), including unwanted visual phenomena, satisfaction, and spectacle independence, among patients who underwent cataract surgery with all of these lenses. Specifically, we examined blended, bilateral, or monovision approaches using the AcrySof IQ ReStor +2.5 D and ReStor +3.0 D. These cohorts were compared with each other and with patients implanted with bilateral PanOptix. We found that the mini-monovision cohort achieved better spectacle independence, particularly at intermediate distances, and lower rates of dysphotopsia than the blended or bilateral multifocal groups, although patient satisfaction was similar across all three cohorts. Compared to these cohorts, bilateral PanOptix trifocal IOLs provided higher rates of patient satisfaction, much higher rates of complete spectacle independence, but also slightly higher rates of dysphotopsia.

Recently, a new IOL, the AcrySof IQ Vivity IOL (Alcon), was introduced. This IOL is the first to mitigate the effects of presbyopia with nondiffractive, extended-depth-of-focus (EDOF) optics. In clinical trials, the lens was shown to deliver monofocal-quality distance vision with excellent intermediate and functional near vision, while maintaining a monofocal-like visual disturbance profile. In a prospective study of early real-world experience, Italian researchers confirmed that the lens provided excellent distance and intermediate, while patients needed some spectacle correction at 30 cm.

To date, patient-reported satisfaction beyond glare/halo has not been compared between the AcrySof IQ PanOptix and the AcrySof IQ Vivity IOLs. This study was designed to assess how satisfaction rates, spectacle independence, and unwanted visual phenomena with the AcrySof IQ Vivity IOL compare to PROs with the multifocal IOL cohorts previously evaluated.

Materials and Methods

This trial was a prospective, open-label, multicenter analysis of PROs among patients who underwent bilateral cataract surgery at least 1 month previously with AcrySof IQ Vivity or Vivity Toric extended depth of focus IOLs, with a target of plano sphere in both eyes. Comparisons were made to the cohort of PanOptix trifocal patients and two previous cohorts of multifocal IOL patients (blended or mini-monovision) who were recruited prospectively and had responded to a similar PRO questionnaire in a similar postoperative time frame. In those studies, PanOptix patients received either the PanOptix or the PanOptix toric implant bilaterally with a target of plano sphere in both eyes. Among multifocal patients, the “2.5 mini-monovision” cohort received the AcrySof IQ ReStor ActiveFocus +2.5 D or AcrySof IQ ReStor ActiveFocus +2.5 D toric implant bilaterally, with the dominant eye targeted for emmetropia and the nondominant eye targeted for −0.5 D sphere. The blended or “2.5/3.0” cohort was implanted with the AcrySof IQ ReStor ActiveFocus +2.5 D implant in the dominant eye and the AcrySof IQ ReStor +3.0 D multifocal lens in the nondominant eye.

Across all cohorts, all eyes underwent phacoemulsification cataract surgery using either a manual or a femtosecond laser-assisted technique, with a target refraction as close to the established refractive target as the available lens powers allowed, erring on the side of the first myopic lens choice when necessary. Patients were excluded from all cohorts if they had significant ocular pathology that could alter their perception of the outcome of surgery, or if they had more than grade 1 posterior capsule opacity (PCO).
In both the present study and our previously-published PanOptix study,\(^\text{11}\) patients were excluded if they had residual refractive error in either eye of >0.5 D sphere or >0.75 D cylinder. To account for the difference in exclusion factors between these studies and our blended/mini-monovision study,\(^\text{10}\) we performed a subgroup analysis in which the raw data from the earlier study was examined to determine overall satisfaction and overall spectacle independence (our primary and secondary endpoints) for the subset of 2.5 mini-monovision and 2.5/3.0 cohort patients meeting the stricter refractive criteria of the later studies (residual refractive error within 0.5 D sphere and 0.75 D cylinder).

Patients were asked to complete a validated questionnaire, assisted by a research staff member, that evaluated their satisfaction with the surgery and with their spectacle independence (See Supplemental Information). The PRO questionnaire (Research InSight, LLC, Laguna Beach, Ca, USA) was specifically developed and validated to evaluate the effect of unwanted visual phenomena on patients who have undergone cataract surgery with presbyopia-correcting lenses, as well as satisfaction and spectacle independence. The assessment of these subjective outcomes differentiates this questionnaire from the National Eye Institute Visual Function Questionnaire-14 (VF-14 QOL) and other general-use visual function questionnaires. This questionnaire has been available for use in U.S.-based cataract practices since 2014 and has been used in our prior studies, as well.\(^\text{11,14,15}\)

To determine the sample size needed for this analysis, a calculation was performed based on a 10% margin of error, a 95% confidence interval, and a response distribution of 80%. This resulted in a sample size of 62 patients.

All aspects of this study were conducted under the surveillance of Aspire Institutional Review Board (Santee, CA, USA) following the principles of the Declaration of Helsinki, and patients completed an informed consent process to participate. Reasonable requests to the corresponding author for original data will be honored for a period of 2 years from the publication date of this study.

**Results**

**Demographics**

Sixty patients with a mean age of 69±9.9 years (range 41–99) were enrolled in the study. There were no statistically significant demographic differences between the Vivity cohort and the three comparator cohorts (p = 0.78, Table 1). A higher percentage of patients in the Vivity (n=52, 88%) and PanOptix cohorts (n=52, 88%) underwent femtosecond laser-assisted cataract surgery compared to the 2.5 mini-monovision cohort (n=57, 56%) or the 2.5/3.0 cohort (n=18, 22%).

In the subgroup analysis, 74 patients in the 2.5 mini-monovision cohort (73%) met the residual refractive error criteria, as did 33 patients (80%) in the 2.5/3.0 cohort.

**Glare and Halos**

Patients in the Vivity cohort reported significantly less glare and halos than did those in other cohorts. In response to the question, “How much do you notice glare or halos around lights in dim light situations?” 51 Vivity patients (85%) responded “none” or “just a little,” compared to 69%, 75%, and 71% for Panoptix, 2.5 mini-monovision, and 2.5/3.0, respectively (p<0.03 vs Panoptix, p< 0.05 vs 2.5/3.0 and 2.5 mini-monovision, Chi-squared test). Among Vivity patients, 28 (47%) responded “none,” compared to 37%, 42%, and 33% for Panoptix, 2.5 mini-monovision, and 2.5/3.0, respectively (p<0.02 vs Panoptix, p< 0.03 vs 2.5/3.0 and 2.5 mini-monovision, Chi-squared test). Vivity patients were significantly less likely to notice glare and halos “a fair amount” or worse compared to all other IOL cohorts. (p<0.02 vs Panoptix, p<0.03 vs 2.5/3.0 and 2.5 mini-mono, Chi squared test). The distribution of responses to this question is shown in Figure 1.

**Spectacle Independence**

Overall spectacle independence (Figure 2) for all visual activities combined was comparable for Vivity, mini-monovision, and 2.5/3.0 and significantly higher in the PanOptix cohort.

---

### Table 1 Demographics

<table>
<thead>
<tr>
<th></th>
<th>2.5/3.0</th>
<th>2.5 Mini-Mono</th>
<th>PanOptix</th>
<th>Vivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (meeting criteria)</td>
<td>89</td>
<td>102</td>
<td>59</td>
<td>60</td>
</tr>
<tr>
<td>Age (yrs): Mean ± SD</td>
<td>72.1 ± 7.6</td>
<td>71 ± 8.1</td>
<td>69 ± 9.6</td>
<td>69 ± 9.9</td>
</tr>
<tr>
<td>Age range</td>
<td>52–99</td>
<td>35–91</td>
<td>41–100</td>
<td>41–99</td>
</tr>
<tr>
<td>Femtosecond laser surgery</td>
<td>18 (22%)</td>
<td>28 (27%)</td>
<td>52 (88%)</td>
<td>52 (88%)</td>
</tr>
</tbody>
</table>

---
the Vivity cohort, 33% of patients said they “never” needed glasses for any activity versus 83% of patients in the Panoptix cohort, 36% in the 2.5 mini-monovision cohort, and 31% in the 2.5/3.0 cohort (p < 0.0001, Chi-squared test). Use of glasses “frequently or always” was reported by 27% of patients with Vivity, 3% with PanOptix, 11% with 2.5 mini-monovision, and 34% with 2.5/3.0 (p < 0.0001 for PanOptix vs all other cohorts, Chi-squared test).

No Vivity patients required spectacles for driving or sports/hobbies; one (2%) Vivity patient required glasses for television (Table 2). For computer use, a low rate of ≤20% reported needing spectacles across all lens cohorts (Table 2). For reading, glasses were needed “some of the time” for 65% of Vivity cohort patients, 17% of PanOptix patients, 64% with 2.5 mini-monovision, and 60% with 2.5/3.0 (p < 0.0001 for PanOptix vs all three other cohorts, Chi-squared test).
There were no statistically significant differences in outcomes between patients who underwent femtosecond laser-assisted cataract surgery and those who underwent manual phacoemulsification.

In the subgroup analysis (those with <0.5 D of residual sphere and <0.75D of residual cylinder), complete spectacle independence was reported by 33% of patients with Vivity, 83% with PanOptix, 35% with 2.5 mini-monovision, and 33% with 2.5/3.0 (p < 0.0001 for PanOptix vs all three other groups, Chi-squared test).

**Patient Satisfaction**

No statistically significant differences were noted in overall satisfaction among the cohorts, with “very satisfied” or “somewhat satisfied” being reported by 95% of the Vivity cohort, 97% of the PanOptix cohort, 93% of the 2.5 mini-monovision cohort, 92% of the 2.5/3.0 cohort (p < 0.001, Chi squared test). Conversely, one patient (2%) in the Vivity cohort, one patient (2%) in the PanOptix cohort, four patients (4%) in the 2.5 mini-monovision cohort, and four patients (4%) in the 2.5/3.0 cohort reported they were either “very” or “somewhat” dissatisfied with their vision. Qualitative analysis of free-text responses from patients who reported dissatisfaction showed that dissatisfaction was generally related to unwanted visual phenomena (glare/halos) in the PanOptix cohort and the need for reading glasses in the Vivity and other multifocal cohorts. Some patients in all cohorts described ocular surface discomfort or other complaints (ie implant cost) that were not related to the quality of the implants themselves or to the patients’ vision.

![Table 2 Patient-Reported Spectacle Dependence (Response to the Question, “Do You Ever Need to Use Spectacles for the Following Activities?”)](https://doi.org/10.2147/OPTH.S347382)

<table>
<thead>
<tr>
<th>Activity</th>
<th>2.5/3.0 (N=89)</th>
<th>2.5 Mini-mono (N=101)</th>
<th>Panoptix (N=59)</th>
<th>Vivity (N=60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reading</td>
<td>60%</td>
<td>64%</td>
<td>17%</td>
<td>65%</td>
</tr>
<tr>
<td>Computer</td>
<td>20%</td>
<td>0%</td>
<td>0%</td>
<td>10%</td>
</tr>
<tr>
<td>Driving</td>
<td>10%</td>
<td>5%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>TV</td>
<td>6%</td>
<td>2%</td>
<td>0%</td>
<td>2%</td>
</tr>
<tr>
<td>Sports/Hobbies</td>
<td>3%</td>
<td>2%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

**Figure 3** Satisfaction ratings of the Vivity lens were similar to other lenses among patients responding “very satisfied” or “satisfied”. Significantly more patients responded “very satisfied” to the Panoptix lens compared to all others.
In the subgroup analysis (<0.5 D of residual sphere and <0.75D of residual cylinder) 95% of Vivity patients reported being “very satisfied” or “somewhat satisfied” overall, compared to 97% of PanOptix patients, 96% of patients with 2.5 mini-monovision, 94% with 2.5/3.0. None of the differences in satisfaction was statistically significant.

Refractive Accuracy
Among patients in the Vivity cohort, 100% had an absolute manifest refraction spherical equivalent (MRSE) within 0.75 D of emmetropia, 93% within 0.5 D, 42% within 0.25 D, and 10% exactly at emmetropia, compared to 100% within 0.75 D, 100% within 0.5 D, 90% within 0.25 D, and 36% at emmetropia in the PanOptix cohort. Values for other lens cohorts are shown in Figure 4.

BCVA
BCVA of 20/20 or better in both eyes was achieved by 41 Vivity patients (68%), 45 PanOptix patients (76%), 61 of the 2.5 mini-monovision patients (65%), and 46 of the 2.5/3.0 patients (64%). BCVA of 20/25 was achieved by 93%, 93%, 90%, and 90%, respectively. All patients had BCVA of 20/40 or better. These differences were not statistically significant. PCO (trace and grade 1+) occurred at a similar rate in all cohorts.

Femtosecond Laser Use
Femtosecond lasers were available to surgeons for all patient cohorts and were used for surgery in 32 of 60 Vivity patients (53%), 52 of 59 PanOptix patients (88%), 28 of 102 2.5 mini-monovision patients (27%), and 18 of 83 2.5/3.0 patients (22%), where these data were recorded (p < 0.002 for PanOptix vs each other group, Chi-squared test).

Discussion
This study examined real-world outcomes achieved with a new, nondiffractive EDOF lens intended to mitigate the effects of presbyopia. We found a significantly lower rate of glare and halo in patients implanted with the AcrySof' IQ Vivity IOL compared to our prior studies with other multifocal IOLs,10,11 Complete spectacle independence in the Vivity lens was substantially lower than in the PanOptix cohort, but comparable to that of the 2.5/3.0 multifocal group and the 2.5 mini-monovision group. While the PanOptix and Vivity cohorts had similarly high rates of spectacle independence for intermediate to distance activities, there was a significant difference for near activities (reading), with PanOptix performing much better, as one might expect given the differences in IOL design. Some authors have suggested that binocular near vision with the Vivity lens may be improved with a mini-monovision target in the nondominant eye.16

Residual refractive error is a common source of postoperative dissatisfaction following implantation of advanced technology IOLs.17–19 In this study, refractive accuracy was high across all cohorts and particularly in the PanOptix (100% ± 0.5 D) and Vivity (93% ± 0.5 D) cohorts. Overall patient satisfaction was high for all the IOLs studied, with “very satisfied” or “somewhat satisfied” being reported by >90% across all lens groups, and
≥95% of those in the PanOptix and Vivity cohorts. This rate of satisfaction with the Vivity IOL is comparable to that achieved in the more tightly-controlled FDA studies of this lens.\textsuperscript{12} Satisfaction may be positively influenced by patients not paying for the procedure in FDA clinical trials or, conversely, negatively influenced by out-of-pocket costs in post-market studies. The high level of satisfaction in this study, therefore, is an important validation of the findings in the Phase 3 study for the Vivity lens.\textsuperscript{12}

As surgeons’ armamentarium of advanced technology IOLs expands, it is worth considering which patients are the best candidates for each IOL type. Glare and halo have been commonly reported side effects of diffractive multifocal IOLs.\textsuperscript{17,20,21} Although night vision symptoms rarely lead to IOL exchange, they do contribute to dissatisfaction.\textsuperscript{22,23} Additionally, patients who are very risk-averse or those who frequently engage in night driving may be counseled against choosing a presbyopia-correcting IOL despite a desire for spectacle independence. Based on the findings of this real-world study, the ideal candidates for the Vivity extended depth of focus IOL may be those who want a greater range of vision but who are also very averse to unwanted visual phenomena or nighttime dysphotopsia. The nondiffractive Vivity IOL may also be a reasonable choice for patients with comorbid ocular disease or aberrated corneas who would not be good candidates for the PanOptix trifocal IOL or other diffractive presbyopia-correcting IOLs. Although data on such patients is limited, there is at least one report of a successful outcome with the Vivity lens in a patient with myotonic dystrophy and the potential for anterior capsular contraction.\textsuperscript{24} Patients who are willing to tolerate some unwanted visual phenomena in exchange for maximal spectacle independence may be best served by a diffractive trifocal or multifocal IOL with the potential to provide stronger reading vision.

There are several weaknesses in the current study. The IOL cohorts represent temporally different patient populations, rather than truly randomized, contemporaneous comparative sample. Every effort has been made, however, to conduct the studies in the same fashion to allow for the closest possible comparison among the cohorts.

Comparisons were made to cohorts from a previous study that did not exclude refractive outliers, which could have introduced unintended biases in favor of the 2.5 monovision and 2.5/3.0 cohorts. To compensate for this potential bias, we performed a subgroup analysis of patients meeting the same refractive criteria, and found no change in the primary or secondary outcomes in this study (satisfaction and spectacle independence) with the more restricted refractive population.

More of the patients in the Vivity and PanOptix cohorts underwent femtosecond laser-assisted cataract surgery (FLACS) than in the other cohorts. This was simply a result of the investigators’ practices trending toward greater adoption of FLACS in the time frame of approval of Panoptix and Vivity. However, manifest refraction and BCVA, a proxy for refractive precision, was similar across all cohorts. The differences in spectacle independence, therefore, are likely related to IOL design rather than the use (or not) of the femtosecond laser.

Patients with significant pathology that would be expected to affect their refractive outcome or satisfaction were excluded from all cohorts, including the Vivity group. Nevertheless, because the Vivity lens can be implanted in less-than-perfect eyes, it is possible that differences in the candidate pools may have affected the satisfaction, spectacle independence, refractive accuracy, and/or glare and halo results. Because this study was intended to be a real-world comparison we believe that comparing this new implant to its predecessors in subtly, yet meaningfully different patient populations is reasonable, much as when researchers compare morbidity of a new heart valve to its precursors when the new valve is implanted in less healthy subjects. Surgeons who consider adopting a new lens are likely to value real-world evidence examining the parameters that matter most to their own patients.

The limitations of the study are offset by its strengths, including the fact that it was a prospective, multicenter study. Future, real-world studies examining the outcomes of Vivity non-diffractive EDOF lenses in compromised eyes would be valuable, as would larger, randomized studies that compare Vivity to other presbyopia-mitigating lens options in normal eyes. As IOL options expand, these results may help guide surgeons in customizing IOL choice to each patient’s expectations and visual demands.

**Conclusion**

The AcrySof IQ Vivity extended depth of focus IOL offers a similar range of uncorrected vision to previous multifocal implants. While the Panoptix trifocal lens showed the highest spectacle independence, the Vivity lens provided a significantly better dysphotopsia profile than any of the lenses in the comparison groups.

**Acknowledgments**

A portion of this study was presented as a poster at the 2021 American Society of Cataract and Refractive Surgery annual
meeting in August, 2021 (Las Vegas, NV). Research InSight Inc. funded this study through an independent investigator-initiated research study grant by Alcon.

Disclosure
Dr John A Hovanesian reports grants from Alcon, during the conduct of the study. Drs Michael Jones and Quentin Allen are consultants for Alcon. The authors report no other conflicts of interest in this work.

References
15. Hovanesian JA. What factors drive the highest patient-reported satisfaction with multifocal IOLs? 2015 ASCRS•ASOA Symposium & Congress. San Diego, California; 2015.